Fig. 1

Generation of ApoeCh mouse model. a Partial amino acid (AA) sequence alignment between human and mouse APOE. The vertical blue arrow denotes the location of the R136S Christchurch variant (rs121918393), shown in red in the mouse ApoeCh sequence. Mouse has human APOE4 type sequence at positions 112 and 158 (underlined). AA differences between mouse and human APOE4 in this region are highlighted in yellow. In panels b, i, k, l and n, sex of individual animals are denoted by pink (female) or blue (male) circles. b Plasma cholesterol in 4 mo WT and ApoeCh HO mice (p = 0.0274). c, d Schematic showing mouse groups and study design of 5xFAD;ApoeCh (c) and PS19;ApoeCh (d) cohorts. e–f Apoe mRNA counts from single-cell spatial transcriptomics in the 5xFAD (e) and PS19 (f) cohorts. Each point represents one cell. g-h APOE protein mean fluorescence intensity (MFI) from single-cell spatial proteomics in the 5xFAD (g) and PS19 (h) cohorts. Each point represents one cell. i,l Quantification of APOE in soluble protein fraction from 5xFAD (i) and PS19 cohort animals (l) measured via ELISA, normalized to total protein concentration. j,m Dot blot analysis of APOE protein in insoluble protein fraction of 5xFAD (j) and PS19 (m) cohort. k,n Quantification of APOE protein in insoluble fraction 5xFAD (k) and PS19 (n) cohort normalized to sample brain weight. n = 2–3 mice/genotype for spatial proteomics. n = 3–6 mice/sex/genotype for cortical protein fractions. Data are represented as mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc tests to examine biologically relevant interactions. Statistical significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001